menu
    • menu
    [{"orgOrder":0,"company":"Jade Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"JADE101","moa":"APRIL","graph1":"Undisclosed","graph2":"Phase I","graph3":"Jade Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jade Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jade Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Jade Biosciences","sponsor":"Aptevo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jade Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jade Biosciences \/ Jade Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Jade Biosciences \/ Jade Biosciences"},{"orgOrder":0,"company":"Jade Biosciences","sponsor":"Aerovate Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Merger","leadProduct":"JADE-001","moa":"Undisclosed","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Jade Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jade Biosciences \/ Jade Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Jade Biosciences \/ Jade Biosciences"},{"orgOrder":0,"company":"Jade Biosciences","sponsor":"Aerovate Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Merger","leadProduct":"JADE-001","moa":"Undisclosed","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Jade Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jade Biosciences \/ Jade Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Jade Biosciences \/ Jade Biosciences"},{"orgOrder":0,"company":"Jade Biosciences","sponsor":"Aerovate Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Merger","leadProduct":"JADE-001","moa":"Undisclosed","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Jade Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jade Biosciences \/ Jade Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Jade Biosciences \/ Jade Biosciences"},{"orgOrder":0,"company":"Jade Biosciences","sponsor":"Fairmount Funds Management LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Jade Biosciences","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Jade Biosciences \/ Fairmount Funds Management LLC","highestDevelopmentStatusID":"2","companyTruncated":"Jade Biosciences \/ Fairmount Funds Management LLC"},{"orgOrder":0,"company":"Jade Biosciences","sponsor":"Janus Henderson Investors","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"JADE101","moa":"APRIL","graph1":"Nephrology","graph2":"Phase I","graph3":"Jade Biosciences","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0.14000000000000001,"dosageForm":"Injection","sponsorNew":"Jade Biosciences \/ Janus Henderson Investors","highestDevelopmentStatusID":"6","companyTruncated":"Jade Biosciences \/ Janus Henderson Investors"}]

    Find Clinical Drug Pipeline Developments & Deals by Jade Biosciences

    Menu

    Jade Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Jade Biosciences

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            Jade Biosciences

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JADE101

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : Janus Henderson Investors

                            Deal Size : $135.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Jade Biosciences Announces $135 Million Private Placement

                            Details : In the public offering, JADE101, an unconjugated antibody targeting APRIL, aims to advance treatment for IgA nephropathy.

                            Product Name : JADE101

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            October 07, 2025

                            Lead Product(s) : JADE101

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : Janus Henderson Investors

                            Deal Size : $135.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Jade Biosciences

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            Jade Biosciences

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JADE101

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Study of JADE101 in Healthy Participants

                            Details : JADE101 is a Antibody drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            July 10, 2025

                            Lead Product(s) : JADE101

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Jade Biosciences

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            Jade Biosciences

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JADE-001

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Recipient : Aerovate Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Jade Merges with Aerovate, Secures $300M in Private Placement Funding

                            Details : The combined company will focus on advancing Jade’s portfolio of novel biologics, including JADE-001, a promising anti-APRIL monoclonal antibody for IgA nephropathy.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 28, 2025

                            Lead Product(s) : JADE-001

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Recipient : Aerovate Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Jade Biosciences

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            Jade Biosciences

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mipletamig

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Aptevo Therapeutics

                            Deal Size : $2.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Aptevo Closes $2M Direct Offering Priced At-The-Market Under Nasdaq Rules

                            Details : The net proceeds from the offering will be used to advance the clinical development of APVO436 (mipletamig), being evaluated for the treatment of Acute Myeloid Leukemia.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            April 22, 2025

                            Lead Product(s) : Mipletamig

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Aptevo Therapeutics

                            Deal Size : $2.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Jade Biosciences

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            Jade Biosciences

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JADE-001

                            Therapeutic Area : Nephrology

                            Study Phase : Preclinical

                            Recipient : Aerovate Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Aerovate Shareholders Approve Merger with Jade Biosciences and All Proposals

                            Details : The combined company will focus on advancing Jade’s portfolio of novel biologics, including JADE-001, a promising anti-APRIL monoclonal antibody for IgA nephropathy.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 21, 2025

                            Lead Product(s) : JADE-001

                            Therapeutic Area : Nephrology

                            Highest Development Status : Preclinical

                            Recipient : Aerovate Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Jade Biosciences

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            Jade Biosciences

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JADE-001

                            Therapeutic Area : Nephrology

                            Study Phase : Preclinical

                            Recipient : Aerovate Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement

                            Details : The combined company will focus on advancing Jade’s portfolio of novel biologics, including JADE-001, a promising anti-APRIL monoclonal antibody for IgA nephropathy.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 31, 2024

                            Lead Product(s) : JADE-001

                            Therapeutic Area : Nephrology

                            Highest Development Status : Preclinical

                            Recipient : Aerovate Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Jade Biosciences

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            Jade Biosciences

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery

                            Sponsor : Fairmount Funds Management LLC

                            Deal Size : $80.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Jade Biosciences Launches with $80M to Develop Therapies for Autoimmune Diseases

                            Details : The funding will be used to support Jade's plans to develop targeted therapies for indications with high unmet need across inflammation and immunology.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 01, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery

                            Sponsor : Fairmount Funds Management LLC

                            Deal Size : $80.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth